Juergen Wolf

6.8k citations

92 papers · 1.8k indexed · h-index 22

Impact in

Oncology top 2%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
Pulmonary and Respiratory Medicine top 2%
- Lung Cancer Treatments and Mutations

Papers in ⓘ

Pulmonary and Respiratory Medicine 64
- Lung Cancer Treatments and Mutations 57
- Lung Cancer Diagnosis and Treatment 15
Oncology 49
- Lung Cancer Research Studies 23
- Colorectal Cancer Treatments and Studies 17
- Cancer Immunotherapy and Biomarkers 7

Co-authors: Volker Diehl (3 shared papers)Enriqueta Felip (16 shared papers)Johan Vansteenkiste (7 shared papers)Michael Hallek (5 shared papers)Daniel Shao-Weng Tan (16 shared papers)Jan Gaertner (4 shared papers)Raymond Voltz (4 shared papers)Egbert F. Smit (15 shared papers)
Journals: Journal of Clinical Oncology (63 papers)Journal of Thoracic Oncology (4 papers)Cancer Research (3 papers)Journal of Palliative Medicine (2 papers)The Lancet Respiratory Medicine (2 papers)
Partner nations: Germany United States Switzerland

In The Last Decade

Juergen Wolf

85 papers receiving 1.8k citations

Peers

Countries citing papers authored by Juergen Wolf

Since Specialization

Citations

This map shows the geographic impact of Juergen Wolf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juergen Wolf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juergen Wolf more than expected).

Fields of papers citing papers by Juergen Wolf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Juergen Wolf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juergen Wolf. The network helps show where Juergen Wolf may publish in the future.

Co-authors

The 25 scholars most cited alongside Juergen Wolf, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Juergen Wolf Line = papers co-authored together Juergen Wolf links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 92 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer JAMA ·Pasi A. Jänne, Michel M. van den Heuvel, Fabrice Barlési, Manuel Cobo, Julien Mazières, Lucio Crinò, С. В. Орлов, Fiona Blackhall, Juergen Wolf, Pilar Garrido, Artem Poltoratskiy, G Mariani, Dana Ghiorghiu, Elaine Kilgour, Paul D. Smith, Alexander Kohlmann, David Carlile, David Lawrence, Karin Bowen, Johan Vansteenkiste	2017	249
2	Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP) Journal of Thoracic Oncology ·Rafał Dziadziuszko, Egbert F. Smit, Urania Dafni, Juergen Wolf, Bartosz Wasąg, Wojciech Biernat, Stephen P. Finn, Roswitha Kammler, Zoi Tsourti, Manuela Rabaglio, Barbara Ruepp, Heidi Roschitzki‐Voser, Rolf A. Stahel, Enriqueta Felip, Solange Peters	2019	107
3	Secondary Myeloid Leukemia and Myelodysplastic Syndromes in Patients Treated for Hodgkin’s Disease: A Report From the German Hodgkin’s Lymphoma Study Group Journal of Clinical Oncology ·Andreas Josting, S. Wiedenmann, Jeremy Franklin, Michael May, Markus Sieber, Juergen Wolf, Andreas Engert, Volker Diehl	2003	106
4	Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma Cancers Cancer Discovery ·Vivek Subbiah, Igor Puzanov, Jean‐Yves Blay, Ian Chau, A. Craig Lockhart, Noopur Raje, Juergen Wolf, José Baselga, Funda Meric‐Bernstam, Jason Roszik, Eli L. Diamond, Gregory J. Riely, Eric J. Sherman, Todd Riehl, Bethany Pitcher, David M. Hyman	2020	86
5	Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study. Journal of Clinical Oncology ·Juergen Wolf, Takashi Seto, Ji‐Youn Han, Noemı́ Reguart, Edward B. Garon, Harry J.M. Groen, Daniel Shao-Weng Tan, Toyoaki Hida, Maja J. De Jonge, Sergey Orlov, Egbert F. Smit, Pierre Jean Souquet, Johan Vansteenkiste, Monica Giovannini, Sylvie Le Mouhaër, Anna Robeva, Maeve Waldron-Lynch, Rebecca S. Heist	2019	84
6	A Case of a Diffuse Large B-Cell Lymphoma of Plasmablastic Type Associated With the t(2;5)(p23;q35) Chromosome Translocation The American Journal of Surgical Pathology ·Patrick Adam, Tiemo Katzenberger, Harald Seeberger, Stefan Gattenlöhner, Juergen Wolf, Claus Steinlein, Michael Schmid, Hans–Konrad Müller–Hermelink, German Ott	2003	77
7	Elevated Serum Levels of CC Thymus and Activation-Related Chemokine (TARC) in Primary Hodgkin's Disease: Potential for a Prognostic Factor Cancer Research ·Martin R. Weihrauch, Oliver Manzke, Marc Beyer, Heinz Haverkamp, Volker Diehl, Heribert Bohlen, Juergen Wolf, Joachim L. Schultze	2005	75
8	Phase I/II Combined Chemoimmunotherapy with Carcinoembryonic Antigen–Derived HLA-A2–Restricted CAP-1 Peptide and Irinotecan, 5-Fluorouracil, and Leucovorin in Patients with Primary Metastatic Colorectal Cancer Clinical Cancer Research ·Martin R. Weihrauch, Sascha Ansén, Elke Jurkiewicz, Caroline Geisen, Zhinan Xia, Karen S. Anderson, Edith Gracien, Manuel Schmidt, Burghardt Wittig, Volker Diehl, Juergen Wolf, Heribert Bohlen, Lee M. Nadler	2005	54
9	Standardizing integration of palliative care into comprehensive cancer therapy—a disease specific approach Supportive Care in Cancer ·Jan Gaertner, Juergen Wolf, Michael Hallek, Jan‐Peter Glossmann, Raymond Voltz	2011	53
10	Efficacy and safety of rovalpituzumab tesirine in patients With DLL3-expressing, ≥ 3^rd line small cell lung cancer: Results from the phase 2 TRINITY study. Journal of Clinical Oncology ·David P. Carbone, Daniel Morgensztern, Sylvestre Le Moulec, Rafael Santana-Dávila, Neal Ready, Christine L. Hann, Bonnie S. Glisson, Afshin Dowlati, Charles M. Rudin, Satwant Lally, Sreeni Yalamanchili, Juergen Wolf, Ramaswamy Govindan, Benjamin Besse	2018	48
11	Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC. Journal of Clinical Oncology ·Alice T. Shaw, Ranee Mehra, Dong‐Wan Kim, Enriqueta Felip, Laura Q.M. Chow, D. Ross Camidge, Daniel Shao-Weng Tan, Johan Vansteenkiste, Sunil Sharma, Tommaso De Pas, Juergen Wolf, Ryohei Katayama, Yi-Yang Yvonne Lau, Meredith A. Goldwasser, Anthony Boral, Jeffrey A. Engelman	2013	47
12	2017–2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer Journal of Thoracic Oncology ·Stefan Zimmerman, Arundhati Das, Shuhang Wang, Ricklie Julian, Leena Gandhi, Juergen Wolf	2019	46
13	Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial. Journal of Clinical Oncology ·Dong‐Wan Kim, Ranee Mehra, Daniel Shao-Weng Tan, Enriqueta Felip, Laura Q.M. Chow, D. Ross Camidge, Johan Vansteenkiste, Sunil Sharma, Tommaso De Pas, Gregory J. Riely, Benjamin Solomon, Juergen Wolf, Michael Thomas, Martin Schüler, Geoffrey Liu, Armando Santoro, Margarida Geraldes, Anthony Boral, Alejandro Javier Yovine, Alice T. Shaw	2014	44
14	Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study The Lancet Respiratory Medicine ·Daniel S.W. Tan, Natasha B. Leighl, Gregory J. Riely, James Chih‐Hsin Yang, Lecia V. Sequist, Juergen Wolf, Takashi Seto, Enriqueta Felip, Santiago Ponce Aix, Maud Jonnaert, Chun Pan, Eugene Y. Tan, Jinnie Ko, Susan E. Moody, Dong‐Wan Kim	2020	43
15	Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M. Journal of Clinical Oncology ·Daniel Shao-Weng Tan, James Chih‐Hsin Yang, Natasha B. Leighl, Gregory J. Riely, Lecia V. Sequist, Enriqueta Felip, Takashi Seto, Juergen Wolf, Susan E. Moody, Kenneth R. Adams, Shu‐Fang Hsu Schmitz, Eugene Y. Tan, Dong‐Wan Kim	2016	36
16	Targeting FGFR1-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398. Journal of Clinical Oncology ·Lucia Nogová, Lecia V. Sequist, Philippe A. Cassier, Manuel Hidalgo, Jean‐Pierre Delord, Martin Schüler, Wan‐Teck Lim, D. Ross Camidge, Reinhard Buettner, Lukas C. Heukamp, Masyar Gardizi, Matthias Scheffler, Kato Kambartel, François Ringeisen, Suman Sen, Randi Isaacs, Maud Joannaert, Caroline Lefèbvre, Juergen Wolf	2014	35
17	Recommending early integration of palliative care — does it work? Supportive Care in Cancer ·Jan Gaertner, Juergen Wolf, Sebastian Frechen, Ursula Klein, Dennis Scheicht, Martin Hellmich, Karin Toepelt, Jan‐Peter Glossmann, Christoph Ostgathe, Michael Hallek, Raymond Voltz	2011	34
18	Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors Kölner Universitäts PublikationsServer (Universität zu Köln) ·Lecia V. Sequist, Phillippe A. Cassier, Andréa Varga, Josep Tabernero, Jan H.M. Schellens, Jean‐Pierre Delord, Patricia LoRusso, D. Ross Camidge, Manuel Hidalgo Medina, Martin Schüler, Mario Campone, G. Gary Tian, Steven Wong, J. Corral, Randi Isaacs, Suman Sen, Diana Graus Porta, Swarupa G. Kulkarni, Caroline Lefèbvre, Juergen Wolf	2014	29
19	Implementing WHO Recommendations for Palliative Care into Routine Lung Cancer Therapy: A Feasibility Project Journal of Palliative Medicine ·Jan Gaertner, Juergen Wolf, Dennis Scheicht, Sebastian Frechen, Ursula Klein, Martin Hellmich, Christoph Ostgathe, Michael Hallek, Raymond Voltz	2010	26
20	Risk-adapted robotic stereotactic body radiation therapy for inoperable early-stage non-small-cell lung cancer Strahlentherapie und Onkologie ·Susanne Temming, Martin Köcher, Erich Stoelben, Lars Hagmeyer, De‐Hua Chang, Konrad Frank, Khosro Hekmat, Juergen Wolf, Wolfgang W. Baus, R. Semrau, Christian Baues, Simone Marnitz	2017	26

About Juergen Wolf

Juergen Wolf is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Radiology, Nuclear Medicine and Imaging and Genetics, having authored 92 papers that have together received 1.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (57 papers), Cancer Genomics and Diagnostics (24 papers), Lung Cancer Research Studies (23 papers), Colorectal Cancer Treatments and Studies (17 papers), Lung Cancer Diagnosis and Treatment (15 papers), Radiomics and Machine Learning in Medical Imaging (9 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Lymphoma Diagnosis and Treatment (5 papers). The work is most often cited by research in Oncology (1.0k citations), Pulmonary and Respiratory Medicine (914 citations), Cancer Research (282 citations), Pathology and Forensic Medicine (334 citations) and Molecular Biology (630 citations). Juergen Wolf has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Volker Diehl, Enriqueta Felip, Johan Vansteenkiste, Michael Hallek, Daniel Shao-Weng Tan, Jan Gaertner, Raymond Voltz, Egbert F. Smit, Jan‐Peter Glossmann and Gregory J. Riely. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Cancer Research, Journal of Palliative Medicine and The Lancet Respiratory Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact